• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data
    • FAQs

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • FAQs
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)

Aug 15, 2017

SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting

Aug 14, 2017

SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update

Aug 8, 2017

SCYNEXIS to Present at the Canaccord Genuity Growth Conference

Aug 7, 2017

SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis

Aug 3, 2017

New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains

Jun 15, 2017

SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention

Jun 13, 2017

Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078

Jun 5, 2017

Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections

May 24, 2017

Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)

May 11, 2017
RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2021 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us